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ABSTRACT 
 
 
 
 Leukemia develops from the abnormal expansion of leukemic stem cells that have several 
genetic alterations that prevent these cells from differentiating into normal white blood cells. 
Acute myeloid leukemia (AML), one of the most aggressive types of leukemia, is characterized 
by the accumulation of large numbers of abnormal myeloid cells that do not differentiate into 
functional granulocytes or monocytes during the hematopoiesis process. The goal of this project 
was to study the anti-tumor effect of chemotherapy drugs Doxorubicin (Doxo) and Cytarabine 
(Ara-C) as inhibitors of leukemic cells expressing the oncogene CBFB-MYH11, which causes 
AML. This was accomplished by testing these drugs for specificity in vitro against rapidly 
dividing 3T3 cells and slowly dividing ME-1 leukemic cells expressing inv(16). The drugs were 
also tested in vivo establishing their toxicity in WT mice, and determining their efficacy in a 
leukemia transplantation mouse model.  In vitro it was determined that Doxo and Ara-C affect 
the cell cycle of rapidly proliferating 3T3 cells, but have a lesser impact on slower dividing ME-
1 cells.  In vivo WT mice can tolerate up to 10 doses of 6 mg/kg/every other day of Doxo, and 27 
doses of 200 mg/kg/day of Ara-C.  Leukemic mice treated with chemo drugs 4 weeks after 
transplantation survived thirty nine days with treatment. However, mice treated only 1 week after 
transplantation survived only nineteen days with treatment.  Our research shows that two 
important factors in decreasing the toxicity and increasing the efficacy of AML treatment are the 
amount of recovery time post irradiation and the concentration of drug dose.  These therapeutic 
techniques may be used to expand our treatment options for AML.  
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1.0  BACKGROUND 
 
 
 Leukemia is a malignant disease that affects the bone marrow and blood. Currently there 
is an estimated 231,461 people in the United States living with leukemia (Leukemia Facts and 
Statistics, 2009). The most common type of adult leukemia is acute myeloid leukemia (AML). 
Approximately 13,290 Americans were diagnosed with AML in 2008, and 1 out of every 5 
children with leukemia were diagnosed with AML (Leukemia Facts and Statistics, 2009). 
Despite these intimidating statistics, successful treatment options are available for patients 
diagnosed with AML.  One of these options is chemotherapy, which aims to kill as many 
dividing cells as possible and, over time, return blood cell counts to normal levels. This MQP 
report will focus on the toxicity and anti-tumor effects of two first line chemotherapy drugs, 
Cytarabine and Doxorubicin, in AML mouse models and cell lines. 
 
1.1  Hematopoiesis 
 Blood cell formation arises from bone marrow stem cells, a process known as 
hematopoiesis. The bone marrow contains immature cells called hematopoietic stem cells (HSC) 
that will eventually mature into the cellular components of blood. The two main characteristics 
of HSCs are their self-renewal capabilities and their ability to differentiate into a variety of 
specialized cells. There are two different types of HSCs: one type is a long-term stem cell, which 
is self renewable over a long period of time. The second type is referred to as short-term 
stem/progenitor or precursor cell.  These cells are immature cells, with reduced self renewal 
capacity, that are precursors to a fully differentiated cell of the same tissue type (Hematopoietic 
Stem Cells, 2009). While these progenitor cells are capable of proliferating, they do have a 
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limited ability to differentiate into more than one cell type.  In normal blood cell development 
(Figure 1), HSCs develop and differentiate into myeloid or lymphoid progenitor cells, which 
undergo differentiation into red blood cells, platelets, and white blood cells. The pluripotent 
progenitor cell is the precursor for the multi-potential progenitors, the myeloid progenitor cells 
and the lymphoid progenitor cells. The myeloid progenitors (diagram left side) are precursor 
cells for red blood cells, platelets, granulocytes and monocytes. The lymphoid progenitors are 
precursors for B-lymphocytes, T-lymphocytes, and natural killer cells.   
 
Figure 1: Diagram of Normal Hematopoiesis.  This figure denotes the 
differentiation of hematopoietic stem cells into the cellular components 
of blood, an important process in leukemia (Chronic Lymphocytic 
Leukemia Treatment, 2008) 
  
The process of hematopoiesis can be disrupted, and this can have a devastating impact on the 
human system.  If HSCs do not differentiate into other types of normal stem cells, this can lead 
to leukemia, which is described in the following section.  
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1.2  Leukemia 
 Leukemia is cancer of the blood characterized by the production of irregular white blood 
cells in the bone marrow. Leukemia develops from the abnormal expansion of leukemic stem 
cells that have several genetic alterations that prevent these cells from differentiating into normal 
white blood cells. These immature leukemic stem cells also have rapidly proliferating cell cycles 
and usually a resistance to apoptosis.  
 
1.2.1  Acute Myeloid Leukemia 
 While there are many types of leukemia, categorized by the level of maturation of white 
blood cells and the aggressiveness of the disease, acute myeloid leukemia (AML) is one of the 
most common types of adult leukemia. It begins in the bone marrow, but in the majority of 
patients with AML, this cancer spreads quickly to the blood and invades other parts of the body, 
specifically the lymph nodes, liver, spleen, central nervous system, and testes.  AML is 
characterized by the accumulation of large numbers of abnormal myeloid cells that do not 
differentiate into functional granulocytes or monocytes during the hematopoiesis process 
(Bonnet and Dick, 1997).  Granulocytes are white blood cells that contain enzymes that destroy 
microbes. There are three different types of granulocytes: neutrophils, basophils, and 
eosinophils, distinguished by the size and color of their granules. Monocytes are also white blood 
cells and form in the bone marrow to become blood-forming monoblasts, which eventually 
develop into mature macrophages (What is Acute Myeloid Leukemia?, 2007).  Macrophages 
destroy bacteria and can recognize germs to help B-cells create antibodies to fight these cells. 
The types of blood cells mentioned above are shown below in Figure 2. 
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Figure 2: Photomicrographs of the Various Types of Normal White Blood Cells.  
Figure 2A1 is a small lymphocyte, with a platelet in the upper right hand corner. Figure 
2A2 shows a large lymphocyte. Figure 2A3 is a neutrophil, figure 2A4 is an eosinophil, 
figure 2A5 is a monocyte, and figure 2A6 contains two neutrophils and a monocyte, on 
the left. (Fredrickson and Harris, 2000). 
 
1.2.2  CBFB-MYH11 Gene 
 In the hematopoiesis process of an AML patient, the fusion oncoprotein CBFβ-SMMHC 
(smooth muscle myosin heavy chain) causes the development of pre-leukemia stem cells (PSC) 
from HSCs, which leads to the emergence of abnormal myeloid progenitors (AMP) that do not 
exhibit normal myeloid differentiation (Kuo et al, 2006).  With additional mutations, AMPs 
become leukemia stem cells (LSC) that expand into AML. This process is shown in Figure 3.  
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Figure 3: Development of Acute Myeloid Leukemia.  Diagram shows 
the development of AML from hematopoietic stem cells (Castilla, n.d) 
 
 Clonal chromosomal abnormalities in blast cells from leukemia patients have shown that 
AML can develop from chromosomal translocations that mainly affect transcription factors. The 
heterodimeric transcription complex core-binding factor (CBF) is a regulator of gene expression 
during blood cell development.  It consists of a DNA binding α subunit, encoded by one of the 
RUNX genes, and a β subunit, encoded by the CBFB gene (Castilla, 2006). The CBF factor is 
the most common target of chromosomal rearrangements in AML, specifically the inversion of 
chromosome 16 [inv(16)] (Castilla, 2006).  Approximately 12% of AML patients carry the 
inversion in chromosome 16 (Castilla, 2006).   CBFB forms a heterodimer with RUNX1 (runt-
related transcription factor 1), which is a heterodimeric transcription factor that binds to the core 
element of several promoters and enhancers (Runt-Related Transcription Factor 1, 2009). 
Translocations, such as the inv(16) mutation, alter the RUNX1 and CBFB genes to create fusion 
proteins that have dominant effects in the development of leukemia. The fusion gene CBFB-
MYH11, which encodes the CBFβ- SMMHC fusion protein, is present in almost all cases of 
subtype M4 AML (Castilla, 2004).  
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1.2.3  Treatment for AML 
 There are several different treatment options for patients suffering from AML. The best 
treatment option depends on the subtype of AML and the cytogenetic study of the leukemic cells. 
However, the major treatment used for patients with AML is chemotherapy. Chemotherapy 
treatments are generally divided into two phases: remission induction and post-remission therapy 
(consolidation) (What is Acute Myeloid Leukema?, 2007). The purpose of remission induction is 
to destroy all leukemic cells. This is accomplished by treatment with a combination of two 
chemotherapy drugs, Ara-C and an anthracycline drug, such as daunorubicin. Since remission 
induction does not often kill all leukemic cells, a second treatment phase, consolidation, is 
needed to fully treat the leukemia and prevent relapses. One of the consolidation treatments for 
AML usually includes several cycles of high dose Ara-C therapy (What is Acute Myeloid 
Leukemia?, 2007). This therapeutic option has resulted in remission four years post-treatment in 
40% of patients with AML under 60 years of age (What is Acute Myeloid Leukemia?, 2007). 
However, CBFB-MYH11-positive AML cases are most frequently seen in patients over 60 years 
of age. The overall five year survival of AML patients over 60 years of age with CBFB-MYH11 
is 20%. Therefore, intensive therapies are not recommended for this age group.  
 
1.2.4  Mouse Models 
 The purpose of mouse model systems in leukemic research is to provide researchers with 
a platform to develop and explore therapeutic approaches for treating different types of leukemia. 
These models provide a controlled environment where therapies that would be impossible or 
difficult to be tested on humans can be analyzed. Mice are useful because they can be designed 
to have certain phenotypic or genotypic characteristics that can serve as a control. The laboratory 
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mouse, Mus musculus, is one of the best model systems for cancer investigations due to various 
factors that include: its small size and propensity to breed in captivity, lifespan of 3 years, 
extensive physiological and molecular similarities to humans, and an entirely sequenced genome 
(Frese and Tuveson, 2007).  
With respect to leukemia, there are many specific advantages to using mice as 
hematopoietic cancer models. One advantage is the genetic diversity of the mice can be regulated 
to mimic some of the genetic mutations known to induce the disease. Some types of acute 
leukemia involve several cooperating mutations; however to facilitate an investigation of the role 
of each mutation, mouse models can be designed to only have one mutation within its germline. 
Alternatively, multiple oncogenic mutations can be designed into the model by crossbreeding or 
other strategies (Braun et al., 2008).  Another advantage to using mice as hematopoietic cancer 
models is there are widespread similarities between human and murine hematopoiesis, so the 
effects of oncogenic mutations on the mouse model may be similar to the effects shown in 
humans. In addition, hematopoietic malignancies are almost always transplantable into mouse 
models (Braun et al., 2008). As a result of these reproduced malignancies, controlled 
experiments can be performed in vivo to understand the effects of therapeutic techniques on the 
mouse’s system. A final advantage is the clear disease endpoints present in a mouse model. 
Intermediate endpoints of clinical appearance, peripheral blood counts, and/or lymphadenopathy 
are all clear indicators of the effects of therapeutics on the progression of the disease (Braun et 
al., 2008). Overall, using mice as hematopoietic cancer models has proven to be very useful in 
discovering new methodologies for the detection, management and treatment of cancer in 
humans. 
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 This MQP project will utilize a mouse model that was transplanted with leukemic cells 
that carry the inv(16) mutation, as this mutation expresses the fusion gene CBFB-MYH11. This 
lab uses conditional CBFB-MYH11 knock-in mouse models to show that this gene produces 
AMPs that will lead to AML, along with other mutations that can provide proliferation and/or 
survival advantage of the AML cells (Castilla, n.d.).  The leukemic cells transplanted into the 
129 SvEv mouse models in this project were collected from the peripheral blood, bone marrow, 
and spleen of the CBFB-MYH11 knock-in mouse model, to ensure that the inv(16) mutation was 
present and AML was expressed. The mice transplanted with leukemic cells provide a solid 
model to study the effect of treatment with chemotherapy drugs on AML. 
 
1.3  Chemotherapy Drugs 
 Chemotherapeutic drugs were first introduced in 1945, when research was done on 
nitrogen mustards and its use in the treatment of leukemias and other cancers. Since that time, 
over sixty drugs have been registered in the United States as treatments for cancer, and although 
significant strides have been made, there are still many problems with these drugs that need 
further improvement, such as high toxicity and low specificity.  One of the main problems is that 
many anticancer agents evoke different responses in different types of cancers. Once a new agent 
has been identified, and testing shows that it is effective in treating one type of cancer; great 
effort is devoted to test the same drug in various combinations for different classes of cancer. 
While this course of action has led to some advances in the treatment of many cancers, 
significant increases in survival will only occur if selectivity of present-day anticancer agents can 
be increased or new classes of more selective agents can be discovered. This is a difficult task 
because currently, no existing laboratory tests can accurately predict which chemical will be 
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effective against a particular class of human cancer. Tests can only confirm or deny a 
compound’s anticancer property. Due to these shortcomings in research and the development of 
new drugs that specifically target certain classes of cancers, as a general trend, cancer mortality 
has changed little over the past forty years (Connors, 1996). 
 Another problem which arose in the field of chemotherapy was the toxicity of most 
anticancer drugs.  One of the promising fields of research by medicinal chemists is the 
development of analogs of anthraquinones with lower toxicity that maintain the anticancer effect. 
Although considerable research efforts have decreased the cytotoxic effects of many cancer 
drugs, toxicity remains a problem that hinders cancer therapy.  
 
1.3.1  Doxorubicin 
Doxorubicin (Doxo) is an anthraquinone anticancer agent composed of an amino sugar 
(daunosamine) linked by an O-glycosidic bond to an aglycone (doxorubicinone) (Figure 4). The 
drug has been used for more than 20 years in the treatment of patients with certain types of 
leukemias, lymphomas, soft tissue sarcomas, as well as cancers of the bladder, breast, stomach, 
lung, ovaries, thyroid, multiple myeloma, and others (Lipshultz, 1991). 
 
Figure 4: Diagram of the Chemical Structure of 
Doxo.  (Doxorubicin, n.d.) 
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The exact mechanism of action of Doxo is complex and still somewhat unclear, though it 
is thought to interact with DNA by intercalation and inhibition of macromolecular biosynthesis. 
This inhibits the progression of the enzyme topoisomerase II, which unwinds DNA for 
transcription (Gerwitz, 1999). Doxo stabilizes the topoisomerase II complex after it has broken 
the DNA chain for replication, preventing the DNA double helix from being resealed and 
thereby stopping the process of replication (Ping-Hu, 1996). The planar aromatic chromophore 
portion of the molecule intercalates between two base pairs of the DNA, while the six-membered 
daunosamine sugar sits in the minor groove and interacts with flanking base pairs immediately 
adjacent to the intercalation site, as evidenced by several crystal structures. (Ping-Hu, 1996).  
 
1.3.2  Treatment With Doxo  
Doxo is rapidly and broadly distributed in humans as a chemotherapy treatment, and 
accumulates in irrigated tissues such as liver, lung, kidney, etc. and especially heart.  During the 
past three decades, a standard of care regimen with doxorubicin has been established for AML 
patients. Typically, patients have been treated with the cell-specific agent Ara-C 100 mg/m2/d by 
continuous infusion for 7 days, and Doxo at a dosage of 45 to 60 mg/m2/d intravenously for 3 
days (Tallman, 2005). A plethora of studies have tested various dosages, combination treatments, 
and/or standard therapy followed by high doses of Ara-C.  But even with all the testing and 
research, “the optimal dose, schedule and number of cycles of consolidation chemotherapy for 
patients with AML who achieve CR have not been established” (Tallman, 2005). Despite 
reported advantages of any one laboratory tested approach, no approach has proven to be 
definitively better than the standard drug combination regimen described previously, which is 
described in the table below.  
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Table 1. Therapeutic Strategies in AML and Relapsed or Refractory AML 
Strategy Comments 
AML 
 
 
 Induction      
Daunorubicin 45-60 mg/m2 for 3 days or 
alternative anthracycline or the 
anthracenedione mitoxantrone with cytarabine 
100 mg/m2 for 7 days   
  
 
  
 
  
 
  
 
 
 Optimal dose of anthracycline is unknown.   
 
 No definitive evidence that any anthracycline or 
the anthracenedione mitoxantrone is better at any 
age.   
 
 Standard regimen is effective in all cytogenetic 
subtypes.   
 
 No evidence that addition of high-dose 
cytarabine (HiDAC) or etoposide is essential.   
 
 The induction regimen should not be attenuated 
for older adults.   
After remission*      
 HiDAC 1-3 g/m2 over 1-3 hours for 3-6 days 
x 1-4 cycles   
  
 
 Optimal dose, schedule, and number of cycles of 
HiDAC are unknown.   
 
 Although HiDAC is clearly effective, groups 
using different intensive regimens have reported 
similar data.   
Maintenance therapy     Standard of care in acute promyelocytic 
leukemia (APL); role in other subtypes is less 
convincing.   
Stem-cell transplantation     Most potent antileukemic strategy, but caution 
is warranted in interpretation of studies that are 
underpowered and often not applicable to current 
practice.   
 
 Relapsed or refractory AML      
Chemotherapy     Rarely curative in any subtype.   
Effective reduction in leukemia-cell burden   
  
 
  
 
  
 
 
 Essential for cure.   
 
 High-dose cytarabine is most effective.   
 
 No evidence that additional drugs are 
beneficial.   
 
 May be effective even if prior exposure to 
cytarabine in induction or consolidation.   
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 Best if first CR is long (more than 6-12 
months).   
 
 Investigational approach is appropriate if short 
CR1 or refractory.   
 
     Allogeneic transplantation   
  
 
 
 Potentially curative.   
 
 Best results if in second CR or in early first 
relapse.   
 
     Autologous transplantation   
  
 
 
 Few reports of cure.   
 
 Best results if in second CR with previously 
harvested stem cells.   
 
     Palliative care     Appropriate for older adults not eligible for 
curative approaches.   
 
(Tallman, 2005) 
 
Currently, with this standard of treatment, approximately 50% to 70% of AML patients 
achieve complete remission (CR). Unfortunately, long term disease-free survival (DFS) is only 
experienced for 20% to 30% of patients, and the majority of patients die from persistent or 
relapsed AML.  In an analysis of 3000 AML patients enrolled in 5 successive clinical trials with 
Ara-C and Doxo for induction and intensive post remission therapy, 62% of patients achieved 
CR, however 76% relapsed or died from the disease. Fortunately, overall survival rates have 
improved since the 1970s. The five year overall survival rate of 2000 patients under the age of 55 
has increased from 11 % in the 1970s to 37% in the 1990s (Figure 5). 
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Figure 5: Estimates of Overall AML Survival. (A) Kaplan-Meier product-limit 
estimate of overall survival for patients with newly diagnosed AML treated on ECOG 
protocols between 1973 and 1997.  (B) Kaplan-Meier product-limit estimate of overall 
survival for younger patients (ages 55 years) with newly diagnosed AMLtreated on 
ECOG protocols between 1973 and 1997. (C) Kaplan-Meier product-limit estimate of 
overall survival for older patients (ages > 55 years) with newly diagnosed AML treated 
on ECOG protocols between 1973 and 1997.  
 
 
In 1973, Charlotte Tan, a renowned oncologist at the Sloan-Kettering Cancer Center in 
New York, published a ground breaking paper on the antitumor effects of Doxo. Adriamycin, 
another commercial name of Doxo, was given to 234 patients with leukemia and other types of 
neoplastic diseases. The dose in children was 0.5 mg/kg daily to a total of 2.4 mg/kg per course. 
In adults, the single dose was 0.4 mg/kg to a total of about 2.5 mg/kg in 10 days.  In children 
with acute leukemia previously treated, adriamycin produced complete remissions (12%) and 
good partial remissions (26%). Tumor regressions were seen in 60% of the patients with solid 
tumors. These included lymphoma, embryonal rhabdomyosarcoma, neuroblastoma, Ewing's 
sarcoma, Wilms' tumor, ovarian tumor, hepatoma, embryonal carcinoma, malignant teratoma, 
and retinoblastoma. The therapeutic responses in adults were less consistent, and confined to 
lymphomas and soft tissue sarcomas. Varying degrees of transient electrocardiographic changes 
had been seen in children treated. Adriamycin may have contributed to cardiac failure and death 
in one child, who had recurrent pulmonary metastases. 
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1.3.3  Doxo Side Effects 
While Doxo is used as a primary chemotherapy agent, it also has many adverse side 
effects.  Acute side-effects of Doxo can include nausea, vomiting, and heart irregularities. It can 
also cause neutropenia, a decrease in white blood cell count, as well as complete alopecia (hair 
loss). When the cumulative dose of Doxo reaches 550 mg/m², the risks of developing cardiac 
side effects, including heart failure, dilated cardiomyopathy, and death, dramatically increase. 
Doxo cardiotoxicity is characterized by a dose-dependent decline in mitochondrial oxidative 
phosphorylation. Reactive oxygen species, generated by the interaction of Doxo with iron, can 
then damage the cardiomyocytes (heart cells), causing myofibrillar loss and cytoplasmic 
vacuolization. Accordingly, from the pharmacokinetic point of view, its cardiotoxicity can be 
explained in terms of massive binding in the myocardium, justifying interest in studying the 
distribution of Doxo in different organs and tissues, and especially in the heart (Singal, 1998). 
Unfortunately, the clinical use of Doxo is limited by its toxic effects, such as cumulative dose-
related cardiotoxicity, myelosuppression, and the development of drug resistance (Singal, 1998). 
Additionally, some patients may develop "Hand-Foot Syndrome," characterized by skin 
eruptions on the palms of the hand or soles of the feet that are accompanied by swelling, pain 
and erythemia.  Due to these side effects and its red color, Doxo has earned the nickname "red 
devil” or “red death”.  
 
1.3.4 Doxorubicin Treatment in Mouse Models 
 As previously described, the most effective dose, cycle, and combination of 
chemotherapy has not been established for patients with AML.  In order to accomplish this goal, 
research must first be done in the mouse model before proceeding to clinical trials. In a 2005 
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publication by Brian Lee, mice transplanted with leukemia were tested with various doses of 
Doxo in order to “increase survival” (Lee et al, 2006). It was found that in the AML “mouse 
model, the highest tolerated dose of Doxo is 3 mg/kg for three days” (Lee et al, 2006). Further 
studies will be necessary to establish the most effective treatment for AML in the mouse model, 
and eventually in AML patients.  
 
1.3.5  Cytarabine  
Cytarabine, commonly known as Ara-C, is a chemotherapy agent used primarily for the 
treatment of hematological cancers, such as non-Hodgkin lymphoma and acute myeloid 
leukemia. This agent was first discovered in the 1960s in Europe, and it was not approved for use 
in the US until nine years later, in 1969. Figure-6 shows the chemical structure of Ara-C.  
 
 
Figure 6: Diagram of the Chemical Structure  
of Ara-C.   (DepoCyt, n.d.) 
 
Ara-C is used in standard induction regimens and consolidations/maintenance therapy 
after remission (Yin, 2005).  The drug “is phosphorylated to nucleotide” form, 1-β-D-
arabinofuranosyluracil (Ara-U) by the pymidine nucleoside deaminse (cytidine aminohydrolase), 
which damages DNA during the S phase of the cell cycle (Dedrick et al, 1973). It also inhibits 
both DNA and RNA polymerases and nucleotide reductase enzymes which are needed for DNA 
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synthesis. Any rapidly dividing cells, cancerous or normal, which need DNA replication for 
mitosis, are the most affected by the drug (Yin, 2005) . Studies with Ara-C have shown that it is 
“active only against dividing cells, and does not cause the death of nondividing cell in vitro, even 
at extremely high concentrations (up to 2500 ug/ul)” (Leach, 1969). 
Ara-C is administered in the body through continuous intravenous (i.v.) infusion. The 
drug is metabolized in the liver, kidney, GI mucosa, and granulocytes. The drug, when 
administered intravenously, has an initial distribution half-life of about ten minutes. During the 
initial half life, the majority of the drug is metabolized in the kidney, liver and gastrointestinal 
tract into its inactive metabolite, uracil arabinoside (Dedrick et al., 1973). The secondary 
elimination half life is longer, and lasts one to three hours. The majority of the dose administered 
is excreted via the kidney within one day.   
  This chemo agent is also very toxic to the human body, as well as to mouse models. 
Some toxic effects of the drug are: leucopenia, thrombocytopenia, anemia, GI tract 
abnormalities, fever, conjunctivitis, and pneumonitis (Yin, 2006). 
 Due to its importance as a chemotherapy agent, further research must be conducted to 
establish the most effective dose and schedule of Ara-C in the AML mouse model.  It is 
important to establish the highest tolerated dose, with minimum toxicity and maximum efficacy 
at killing AML cells. From this research, a better therapy and schedule can be developed for 
patients suffering from AML.  
 
1.3.6  Treatment With Ara-C  
 In AML patients, there are two different courses of chemotherapy:  induction remission 
and consolidation.  In induction remission, the patient is treated with one or two sessions of Ara-
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C followed by treatment with daunorubicin.  In post remission therapy, often called 
consolidation, the patient is only treated with Ara-C.  
 
1.3.7 Ara-C Treatment in Mouse Models 
 As previously described, the most effective dose, cycle, and combination of 
chemotherapy has not been established for patients with AML.  In order to accomplish this goal, 
research must first be done in the mouse model before proceeding to clinical trials.  In previous 
studies done with Ara-C, the mouse can be tolerate a treatment of  100 mg/kg every day for 9 
days, followed by a 7 day rest period, and continued with a second session of 9 injections 
(Largaespada, personal communication).  Further studies need to supplement this finding to 
establish the most effective treatment for AML in the mouse model, and eventually in AML 
patients.  
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2.0  PROJECT PURPOSE 
 
 
 
 
As described in the Background section, although Doxo and Ara-C chemotherapeutic 
agents have been shown to be somewhat effective at treating AML in mouse models and 
patients, both drugs still show considerable toxic side effects, and patient survival is limited.  
Thus, the most effective dose, cycle, and drug combination have not yet been established.  The 
goal of this project was to further study the anti-tumor effect of Doxo and Ara-C in vivo in an 
AML mouse model expressing oncogene CBFB-MYH11 and in WT mice, and in vitro against the 
rapidly dividing 3T3 cell line and against the slowly dividing, human leukemic ME-1 cell line 
expressing inv(16). 
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3.0  METHODS 
 
3.1  In Vitro Drug Testing in 3T3 and ME-1 Cell Lines 
 
3.1.1  Propidium Iodide Analysis 
The propidium iodide (PI) flow cytometric assay has been widely used for the evaluation 
of phases of the cell cycle in different experimental models.  It is commonly used to determine 
the percentage of cells in each phase based on the principle that these cells are characterized by 
DNA fragmentation (Riccardi and Nicoletti, 2006). Use of a fluorochrome, such as PI, that is 
capable of binding and labeling DNA makes it possible to obtain a rapid and precise evaluation 
of cellular DNA content by flow cytometric analysis, and subsequent identification of 
hypodiploid cells (Riccardi and Nicoletti, 2006).  
The PI stain can distinguish cells at certain points along the cell cycle; three histogram 
markers identify each phase of the cell cycle, which include the G0/G1 phase, S phase, and 
G2/M phase, with an optional fourth marker that can identify cells in an apoptotic state (Cell 
Cycle Assay, 2009).  Figure 7 shows the state of growth and division of cells at each phase of 
the cell cycle. The apoptotic phase is not shown in the figure; however it is characterized by less 
than 2N DNA.  Absolute counts are established in this essay to determine whether changes in the 
cell cycle result from drug treatments, or are caused by changes in cell number due to cell 
proliferation or cell death (Cell Cycle Assay, 2009).  In this project, the purpose of using the PI 
assay was to determine the effects of Doxo and Ara-C on the cell cycle.   
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Figure-7:  The Phases of the Cell Cycle. (The Phases of the Cell Cycle, 2008). 
 
 
3.1.2  Cell Lines 
The two cell lines used in this assay were the mouse NIH-3T3 cells and the human ME-1 
cell line.  The 3T3 cell line is a mouse fibroblast cell culture established from disaggregated 
tissue of an embryonic albino Swiss mouse (Mus musculus). When these cells were developed in 
the 1960s by George Todaro and Howard Green, they were used to show the difference between 
cell mortality and a cell’s ability to undergo oncogenic transformation (Hill, 2007).  This is a 
rapidly growing cell line, and should be strongly affected by Doxo or Ara-C treatments. 
The ME-1 cell line was established from peripheral blood leukemia cells of a patient with 
acute myelomonocytic leukemia with eosinophilia (M4E0) (Yanagisawa et al, 1991). This cell 
line carries the chromosome abnormality inv(16) (p13; q22) expressing CBFB-MYH11, among 
other mutations. ME-1 cells were found to be monoblastic when cultured in RPMI 1640 medium 
with 10% fetal bovine serum.  However, with the addition of the cytokines, interleukin-3 (IL-3), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), or IL-4, the cells differentiate to 
 25
macrophage-like cells (Li, 2008). The proliferation and differentiation of ME-1 cells by IL-3 or 
GM-CSF are related to the activation of protein kinase C, whereas those by IL-4 involve other 
regulatory systems (Durst, 2003).  ME-1 cells are useful for studying the pathogenesis of M4E0 
and the mechanisms of proliferation and differentiation of leukemic and normal progenitors by 
cytokines.   
 
3.1.3  3T3 Cell Culture 
3T3 cells were plated in a 6-well plate at 2x105 cells per well containing a total of 3 mL 
of cells and Dulbecco's Modified Eagle Medium (DMEM) media containing antibiotic. After a 
24 hour incubation period at 37ºC, Doxo and Ara-C were added to each well. Doxo stock 
solution (2 mg/mL) was added to three wells at volumes of 100 µL, 10 µL, and 1 µL 
respectively.  Ara-C was diluted 10X (to 10 mg/mL) before it was added to two wells at volumes 
of 100 µL and 10 µL. Nothing was added to the final well, which served as a negative control. 
After a second 24 hour incubation period with the chemotherapy drugs, the cells were prepped 
for PI analysis.  
 
3.1.4  ME-1 Cell Culture 
ME-1 cells were plated in nine wells in a 96-well plate with 50,000 cells per well. After a 
24 hour incubation period at 37ºC, the chemotherapy drugs were added to each well. The wells 
contained four different concentrations of Doxo and Ara-C, and a control for each drug only 
containing ME-1 cells. Ara-C was diluted 10X from a powder to a final concentration of 100 
mg/mL. A serial dilution was made for Doxo at concentrations of 2 mg/mL, 0.4 mg/mL, 0.08 
mg/mL and 0.016 mg/mL, and Ara-C at concentrations at 10 mg/mL, 2 mg/mL, 0.4 mg/mL and 
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0.08 mg/mL. Each well contained 200 µL of ME-1 cells followed by 6.7 µL of the diluted 
concentration of either Doxo or Ara-C. Both Doxo and Ara-C were resuspended in the wells to 
avoid the formation of precipitates. After the cells had been treated with Doxo and Ara-C for 24 
hours, they were prepped for PI analysis. 
 
3.1.5  Leukemic Cell Culture 
Leukemic cells were obtained from mice that had AML. These cells were harvested from 
the spleen, bone marrow, and peripheral blood of these mice. The leukemic cells were plated in 
nine wells in a 96-well plate with 50,000 cells per well. After a 24 and 48 hour incubation period 
at 37ºC, the chemotherapy drugs were added to each well. The wells contained four different 
concentrations of Doxo and Ara-C, and a negative control for each drug only contained leukemic 
cells.  Ara-C was diluted 10X from a powder to a final concentration of 0.1 grams/mL. A serial 
dilution was made for Doxo at concentrations of 2 mg/mL, 0.4 mg/mL, 0.08 mg/mL and 0.016 
mg/mL, and Ara-C at concentrations at 10 mg/mL, 2 mg/mL, 0.4 mg/mL and 0.08 mg/mL. Each 
well contained 200 µL of leukemic cells followed by 6.7 µL of the diluted concentration of 
either Doxo or Ara-C. Both Doxo and Ara-C were resuspended in the wells to avoid the 
formation of precipitates. After the cells had been treated with Doxo or Ara-C for 24 and 48 
hours, they were prepped for PI analysis. 
 
3.1.6  Preparation of Cells for PI Analysis 
The media and cells of each well was extracted and spun down at 1,700 g for 10 minutes. 
The supernatant was then aspirated. Next, 300 µL of phosphate buffered saline (PBS) was added 
to resuspend the cell pellet. The cells and PBS were then transferred drop by drop into 5 mL 
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tubes containing 2.7 mL of 70% ethanol in order to fix the cells in whatever phase of the cycle 
they were in. Samples were then sent to the FACS facility where PI was added and analysis was 
performed.   
 
3.2   In Vivo Drug Testing-Toxicity of Doxo and Ara-C in WT Mice 
 Toxicity experiments were performed to determine the toxicity of Doxo and Ara-C on 
normal proliferating cells and the highest tolerated dose (HTD) of each drug. The toxicity 
experiments were tested on 129 SvEv mice. The 129 SvEv mouse is a subline of the 129/J strain. 
The 129/J mouse and its sublines have been used to derive most of the commonly used 
embryonic stem cell lines (Reiners and Singh, 1997). This is an agouti coat-colored murine 
strain.  The toxicity experiments using Doxo in this project were based on previously published 
studies indicating this drug can be tolerated at an injection of 3 mg/kg every 3 days  over a 
period of 7 days (3 total injections) (Lee et al, 2006). The toxicity experiments using Ara-C were 
based on previous studies indicating this drug can be tolerated at 100 mg/kg every day for 9 
injections, followed by a 7 day rest period, and continued with a second session of 9 injections 
(Largaespada, personal communication).  
The 100 mg/mL Ara-C stock was diluted 1:100 with PBS to a final concentration of 1 
mg/mL. The Doxo was also diluted 1:100 with PBS from its original 2 mg/mL serum form, to a 
final concentration of 0.02 mg/mL. The 129 SvEv mice were injected intraperitoneally (i.p.) 
through the course of treatment until they died or it was no longer humane to continue with 
injections. At this point, the mice were euthanized using IACUC protocol A-1266 approved by 
UMASS Medical School.  
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3.2.1  Retro-Orbital Sinus Bleeding 
 To obtain blood for CBC, PI, and FACS analyses, retro-orbital sinus bleeds were 
performed. First, the mouse was anesthetized using 400-500 µL of Avertin. The mouse was then 
held with the forefinger and the thumb tightly at its neck to have access to the eye. To collect the 
blood, small capillary tubes were inserted into the venous sinus laterally at approximately a 45º 
angle. Once the tube entered the peri-orbital venous sinus that fills the bony orbit of the eye of 
the mouse, blood would begin to flow through capillary action (Mouse: Retro-orbital, 2006). 
Once the desired amount of blood was collected, the bleeding was stopped by applying pressure 
with gauze.  
 
3.3  In Vivo Drug Testing:  Efficacy and Toxicity of Doxo and Ara-C in the Leukemia 
Transplantation Model 
 
 Experiments were performed with the leukemia transplantation mouse model to 
determine the toxicity and anti-tumor effects of Doxo and Ara-C on AML cells in vivo. 
Leukemic cells were harvested from the spleen, peripheral blood, and bone marrow of a mouse 
that had AML caused by CBFB-MYH11 expression. These leukemic cells were cryopreserved 
and then thawed when needed.  In these experiments, 5x105 leukemic cells were transplanted 
into each mouse.  The mice used were first irradiated using 650 rads to kill normal bone marrow. 
The leukemic cells were then injected intravenously (i.v) into one of the lateral tail veins of the 
mouse. The mice were given at least one week to recover from the irradiation before beginning 
treatment. Treatment was administered using the same protocol as the toxicity experiments in 
WT mice.   
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3.3.1  FACS Analysis 
 Fluorescence activated cell scanning (FACS) was used to demonstrate the presence of 
malignant cells in peripheral blood and bone marrow suspensions. During these experiments 
FACS analysis was used to identify the progression of leukemia in mouse peripheral blood, 
spleen cells, and bone marrow.  Peripheral blood was collected through retro-orbital bleeding 
into 2mL Eppendorf tubes containing 1mL of red blood cell (RBC) lysis buffer. The cells were 
left in the RBC lysis buffer for 20 minutes to ensure cell lysis occurred followed by five minutes 
of centrifugation at 1,200 g. The supernatant was aspirated and this process was repeated.  FACS 
buffer was added to each tube depending on the size of the pellet and the number of samples 
needed.  Enough FACS buffer was added so that each sample tube contained approximately 50 
µL of solution. 
 In this FACS analysis, antibodies tagged with a fluorescent dye bind specifically to 
receptors on desired cells to determine if leukemia is present in the blood. The primary 
antibodies used in these experiments were labeled with phycoerythrin (PE), one of the most 
common fluorescent dyes used in FACS analysis. These antibodies specifically recognized the 
following cell surface markers: cKit, Gr1, B220, Mac1, and CD3. cKit is present in all leukemic 
cells, and this is an important cell surface marker used to identify certain types of hematopoietic 
(blood) progenitors in the bone marrow. Specifically hematopoietic stem cells (HSC), 
multipotent progenitors (MPP), and common myeloid progenitors (CMP) express high levels of 
cKit.  For this experiment cKit was diluted 1:32 with FACS buffer, Gr1, B220, Mac1 were 
diluted 1:16 with FACS buffer, and CD3 was diluted 1:8 with FACS buffer. The blood samples 
were then put on ice for 20 minutes for staining to occur. The antibodies are light sensitive so it 
was necessary to cover them during this 20 minute period. After this incubation period 1 mL of 
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FACS buffer was added to the samples to wash away any antibodies that had not bound. Then 
the cells were once again centrifuged, and a pellet was obtained. Finally 500 µL of fixing buffer 
(10% formaldehyde in FACS buffer) was added to the pellet and mixed well. The samples were 
transferred into 5mL tubes and sent to the FACS facility for analysis. 
FACS analysis using spleen and bone marrow cells followed the same procedures as the 
preparation for peripheral blood cells. Spleen cells and bone marrow were obtained after mice 
died or were euthanized. Spleen cells were harvested from the deceased mice, crushed using a 
pestle and mortar in RBC lysis buffer, filtered, then spun down to prepare the cells for FACS 
analysis. Bone marrow was harvested from the femur and tibia bones of the mouse. The bones 
were dissected from the muscles and tendons, and placed in a petri dish containing RBC lysis 
buffer. Similar to the spleen cells, the bone marrow was then crushed into a paste and passed 
through a filter, and centrifuged to prepare the cells for FACS analysis using the procedures 
outlined above.  
 
3.3.2  Blood Smears 
 Blood smears were created to study the morphology of the blood cells of the mice. First, 
a small drop of blood was obtained with a capillary tube from the orbital sinus of the mouse. The 
blood droplet was placed on a slide and spread across the surface using a second slide. The slide 
was left to dry for a period of time before staining. Wright Giemsa Staining was used to prepare 
the slide. In order to stain the slide, Coplin jars were prepared with the necessary solutions. Jar 1 
contained fresh methanol, jar 2 contained 30 mL of Wright Giemsa Stain, jar 3 contained 5 mL 
Wright Giemsa Stain, 0.4 mL of Azure Blend, and 30 mL of ddH20, and jar 4 contained 3-5 mL 
of Wright Giemsa Stain and 30mL pH 6.8 phosphate buffer.  The slides were first fixed in 
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methanol for 30 seconds. After each slide was placed in a particular jar, the slides were dabbed 
onto paper towels to soak up excess liquid. Next, the slides were placed in jar 2 for 3 minutes, 
followed by jar 3 for 10 minutes, and jar 4 for 2 minutes. Finally slides were placed into a jar 
with distilled water to remove excess stain, then both sides of the slides were washed gently 
under distilled water. The slides were air dried for several minutes before being viewed under a 
microscope. 
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4.0  RESULTS 
  
 Chemotherapy is the current method of treating AML. The purpose of the first round of 
chemotherapy treatments is remission induction to normalize blood counts and to eliminate as 
many leukemic cells as possible from the blood and bone marrow. Currently, the most common 
treatment regimen for AML is chemotherapy with Doxo and/or Ara-C.  However, these drugs 
have proven to be extremely toxic as they not only target preferentially expanding cells in AML 
but also normal proliferating cells. The most effective dose, cycle, and drug combination in mice 
and cell lines has not yet been established.  In order to further study the anti-tumor effect of 
Doxo and Ara-C as inhibitors of leukemic cells expressing the leukemia oncogene CBFB-
MYH11, we tested the drugs for their in vitro effect on the growth, apoptosis, and differentiation 
of ME-1 inv(16) cells compared to 3T3 cells, and in vivo established the toxicity of Doxo and 
Ara-C in wild type mice to determine the maximum tolerated concentration (MTC), and 
established the efficacy of leukemia drugs in the leukemia transplantation model.  
 
4.1  In Vitro Drug Testing:  PI Staining and FACS Analysis 
 In order to determine the effects of Doxo and Ara-C on the cell cycle, Propidium Iodide 
(PI) staining was done on 3T3 cells and ME-1 cells, treated with various concentrations of the 
drugs and analyzed by FACS after 24 hours of incubation. The PI stain can distinguish cells at 
the G0/G1 phase, S phase, G2/M phase, and an apoptotic state (Cell Cycle Assay, 2009).  3T3 
cells are rapidly proliferating cells, and ME-1 are slow-proliferating cells that contain the 
inv(16)mutation. It was initially expected that the chemo drugs would have a greater effect on 
the ME-1 cell line, a human leukemic cell line, as opposed to the 3T3 cell line.  
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 Figure 8 shows the PI staining and FACS analysis of 3T3 cells treated for 24 hours with 
volumes of Doxo at 100 µl, 10 µl, and 1 µl at a concentration of 2 mg/mL, and volumes of Ara-C 
at 100 µl and 10 µl at a concentration of 10 mg/mL, and control cells. The percentage of cells in 
each phase of the cell cycle is shown in Table II.  Doxo at high concentrations has a very 
cytotoxic effect on 3T3 cells, killing the cells before they enter the cell cycle.  In panel A, the 
majority of cells are in an apoptotic state (left peak), and as the concentration of Doxo decreases 
(B, C), the cells are able to progress further through the cell cycle (middle and right peaks).  In 
parts D and E, Ara-C has a very cytostatic effect on 3T3 cells by preventing the cells from 
proliferating, holding them in the G1 phase.  Very few cells progressed to S or G2/M.  The 
control (F) shows that although the majority of cells are in the G1 phase, a number of cells were 
able to progress along the cell cycle to S phase and G2/M (right peaks).   
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Figure-8: PI Staining of 3T3 Cells Treated With Graded Concentrations of Doxo 
and Ara-C.  The majority of cells treated with Doxo are in an apoptotic state.  The cells 
treated with Ara-C have the highest percentage of cells in G1 phase (cytostatic).  
 
 
 
Table II: Percentages of 3T3 Cells in Each Cell Cycle 
Phase 24 Hours Post Drug Treatment. 
Cells Apoptosis G1 S G2/M
Control 2.19 45.82 17.09 17.14
100 µl Doxo 35.46 19.77 12.25 6.8
10 µl Doxo 18.6 31.03 17.36 10.93
1 µl Doxo 10.36 32.2 18.02 20.06
100 µl AraC 5.48 45.62 12.83 5.24
10 µl AraC 7.78 37.76 11.54 4.19
% of Total Cells
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Figure-9 shows the FACS analysis of the PI staining of ME-1 cells treated with Doxo 
and Ara-C at various concentrations for 24 hours, and the values are quantitated in Table III. 
Cells were treated with Doxo at concentrations of 2 mg/mL, 0.4 mg/mL, 0.08 mg/mL and 0.016 
mg/mL, and Ara-C at concentrations of 10 mg/mL, 2 mg/mL, 0.4 mg/mL, and 0.08 mg/mL. 
Panel A shows that the majority of ME-1 cells treated with 100 mg/mL of Doxo are in G2-M 
phase (right peak), and this pattern continues at the other Doxo amounts tested. This pattern is 
similar to untreated control cells, and to all concentrations of Ara-C tested, indicating neither 
drug had a strong effect on ME-1 cells.   
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Figure-9:  PI Staining of ME-1 Cells Treated With Graded Concentrations 
of Doxo and Ara-C.  Neither drug had a strong observed effect on ME-1 cells at 
the concentrations tested. 
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Table III: Percentages of ME-1 Cells in Each 
Cell Cycle Phase 24 Hours Post Drug Treatment 
Cells Apoptosis G1 S G2/M
ME-1 (Control) 7.48 20.6 3.82 32.5
1:1 Doxo 7.36 19.6 4.01 36.1
1:5 Doxo 6.85 14.9 4.18 28
1:25 Doxo 6.38 16.2 5.11 32.2
1:125 Doxo 5.78 13.5 5.65 35.3
1:1 Ara-C 10.6 16.2 4.94 37.8
1:5 Ara-C 7.39 19 4.49 40.8
1:25 Ara-C 10.9 17.2 4.29 36.7
Total
 
 
Figure 10 shows the PI/FACS analysis on leukemic cells harvested ex vivo from an 
AML mouse model treated with either Doxo or Ara-C at various concentrations for 24 hours 
(Part A) and 48 hours (Part B).  Cells were treated with Doxo at concentrations of 2 mg/mL, 0.4 
mg/mL, 0.08 mg/mL and 0.016 mg/mL, and Ara-C at concentrations of 10 mg/mL, 2 mg/mL, 0.4 
mg/mL, and 0.08 mg/mL.  In each condition tested, the overwhelming majority of cells were in 
an apoptotic state, however even the control cells were in apoptosis, so it was not the drug which 
killed the cells, but rather another unknown factor.  
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Figure 10:  PI Staining of Leukemic Cells Taken Ex Vivo from an AML Mouse 
Model Treated With Graded Concentrations of Doxo or Ara-C.  All cells were 
apopotic in this analysis, including untreated cells. 
 
 
4.2  In Vivo Drug Testing:  Toxicity of Doxo and Ara-C in Wild Type Mice 
 Previous studies have indicated that the two first-line chemotherapy drugs used to treat 
AML, Doxo and Ara-C, are extremely toxic because not only do they target preferentially 
expanding leukemic cells, but also normal proliferating cells. As a result, the optimum treatment 
regimes have not yet been established.  Based on published murine studies, Doxo can be 
tolerated at 3 mg/kg every three days for three times (Lee et al, 2007). Additionally, Ara-C can 
be tolerated at 2 sessions of 100 mg/kg every day injected for nine days per session, with a seven 
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day rest period between sessions.  Using this published schedule of treatment, a lethal 
concentration-25 (LC25), the concentration of drug that kills 25% of the experimental population, 
is expected.  
 In this project, we began by validating the Lee et al (2006) study.   The toxicity of each 
drug was established in wild type (WT) healthy mice.  In all cases, toxicity was evaluated based 
on survival and daily inspection of the mice. Changes in motility, hair appearance, posture, and 
signs of anemia (indicated by pale paws) were also observed. When these physical signs were 
apparent, blood was analyzed for white blood cell (WBC) count, hematocrit (red blood cell 
(RBC) count), and platelets. When the toxicity of the drug caused these symptoms, mice were 
euthanized following procedure detailed in IACUC protocol A-1266 approved by the University 
of Massachusetts Medical School.   However, since the mice survived the initial treatment and 
the expected LC25 results were not obtained (data not shown), different drug concentrations were 
tested to determine the highest tolerated dose (HTD) of each drug in WT mice, which would 
subsequently be used in the leukemia transplantation mouse model. 
 With respect to the HTD testing, an experiment was conducted to validate the previously 
published data that the HTD of Doxo in mice in vivo is 3mg/kg every three days injected three 
times. Two groups (n=4) were injected once every three days for a total of 9 days, at a dosage of 
3 mg/kg or 2mg/kg of Doxo.  If mice were able to survive the third dose, blood samples were 
analyzed for leukocytosis, hematocrit, and platelets (Figure 11). The data indicate that the mice 
given six dosages showed no physical signs of toxicity. Survival was not affected by the drug, as 
100% of the treated mice remained alive (shown in Table IV).   However, the results of the 
bleeding show that the average WBC count and platelet levels decreased slightly at the higher 
dose. These differences are negligible and there is no control for comparison. The standard 
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deviation for the 2 mg/kg was 0.53 for the WBC and 76.0 for the platelets. The standard 
deviation for the 3 mg/kg was 1.13 for the WBC and 46.39 for the platelets. 
 
 
Figure 11: White Blood Cell Count (Left Panel) and Platelet Count (Right Panel) of WT Mice.  The 
mice were treated with either 3 mg/kg or 2 mg/kg every 3 days for 9 days with Doxorubicin.   
 
  
Table IV: Survival of WT Mice Treated with 3 mg/kg or 2 mg/kg 
Every Three Days for 9 Days with Doxorubicin. 
 
Dose 3 mg/kg/day Doxo 2 mg/kg/day Doxo
1 100 100
2 100 100
3 100 100
4 100 100
5 100 100
6 100 100
% of Living Mice
 
 
 The experiment described above was repeated, but with the addition of two groups of 
four mice. The first and second groups of mice were treated with 3 mg/kg and 2 mg/kg every 
three days for 27 days, along with the third group of mice treated with PBS, to serve as a control 
group. A fourth group was later added and treated with 4 mg/kg of Doxo every three days for 12 
days (data not retrieved). The purpose of including the 4 mg/kg group was to test the tolerance 
0
0.5
1
1.5
2
2.5
2mg Doxo 3mg Doxo
A
v
e
ra
g
e
 W
B
C
 C
o
u
n
t 
( 
1
0
3
/u
L)
0
100
200
300
400
500
2mg Doxo 3mg Doxo
P
la
te
le
ts
 (
1
0
3
/u
l)
 41
parameters of the mice. These mice were able to tolerate four injections of 4 mg/kg every three 
days. In this experiment, mice were able to survive past three dosages, up to nine total dosages 
(Table V). Although mice did have slightly affected motility, there were no other physical signs 
of toxicity, and survival was not affected.  Blood analysis was performed after the third dose 
(Figure 12), and the mice were euthanized after the final fourth dosage.  All mice, except for one 
mouse administered at the 3 mg/kg dosage, are below the normal range. There is no significant 
difference between the levels of WBCs for each group, including the PBS control. These cell and 
platelet counts may have been affected by the inaccuracy of the cell blood counter (CBC) 
machine. The standard deviation for the 2 mg/kg dosage was 0.39 for the WBC and 21.27 for the 
platelets. The standard deviation for the 3 mg/kg dosage was 0.61 for the WBC and 20.95 for the 
platelets. 
 
  
Figure 12: White Blood Cell Count and Platelet Count of WT Mice.  Mice were  
treated with 3 mg/kg or 2 mg/kg  every three days with Doxorubicin for 27 Days.  
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Table V: Survival of WT Mice Treated With 3mg/kg of Doxo, 
2mg/kg of Doxo, or PBS, Every Third Day for 27 Days. 
Dose 3mg/kg/day Doxo 2mg/kg/day Doxo PBS
1 100 100 100
2 100 100 100
3 100 100 100
4 100 100 100
5 100 100 100
6 100 100 100
7 100 100 100
8 100 100 100
9 100 100 100
% of Living Mice
 
 
 Since these dosage experiments were performed twice, and the toxicity of the drugs had 
no significant effect on the WT mice, we next tested a higher dose of 6 mg/kg every other day 
for ten total injections. After seven doses, the mice began to show signs of anemia (pale paws) 
and their coats became dull and scruffy. Also, their posture and motility decreased significantly.  
Figure 13 shows the survival of the mice. All of the mice died by day 28. 
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Figure 13: Kaplan-Meier Curve of WT Mice Treated With 6mg/kg 
Every Other Day with Doxo for 27 Days.  All WT mice died after 27 
days at this high Doxo dose. 
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With respect to Ara-C, according to published data mice can tolerate 2 sessions of 100 
mg/kg every day for nine days per session, with a seven day rest between sessions (Largaespada, 
personal communication). In our initial Ara-C experiment (data not shown), mice were able to 
survive both 9-day sessions at a dosage of 100 mg/kg.  Since our Doxo experiments allowed 
dosages much higher than previously published values, we also increased the dose of Ara-C to 
200 mg/kg to a group of four mice (data not shown). The mice were able to tolerate the two 9-
day sessions, so a third session was administered immediately following a fourteen day rest 
period between the second and third session. Figure 14 shows the survival curve of this group of 
mice. The mice were administered a total of 27 dosages with an LC25 over a 48 day period. 
 
 
Figure 14: Kaplan-Meier Curve of WT Mice Treated with 200 mg/kg of Ara-
C.  The dose regime for Ara-C for this experiment was 200 mg/kg every day for 
nine days, then a 7 day rest period, then another 9-day injection session, then a 14-
day rest period, then a third 9-day injection session (48 days total). 
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4.3  In Vivo Drug Testing:  Efficacy and Toxicity of Doxo and Ara-C in the Leukemia 
Transplantation Model 
 
 The HTD of both Doxo and Ara-C established in section 4.2 was used to test the efficacy 
of each chemo drug in a mouse leukemia transplantation model. We tested the delay and 
recovery from leukemia development at the HTD of Doxo or Ara-C in 129 SvEv mice irradiated 
and transplanted with AML.  Leukemia progression during and after chemo treatments was 
monitored by daily inspection of the phenotypic behavior of the mice, as well as analyzing blood 
samples through FACS, and cell morphology through microscopy of blood smears. The 
phenotypic behaviors that signify leukemia development include decreased mobility, distended 
abdomen (as a result of an enlarged spleen), and change in hair appearance (hair becomes 
discolored and dull).  The mice were euthanized before the leukemia reached an advanced stage 
following the procedure detailed in the IACUC protocol for Dr. Castilla A-1266, approved by 
UMASSMED.  Mice that died during the experiment were analyzed by necropsy for an enlarged 
spleen to confirm that leukemia caused their death.  
Figure 15 shows the survival curves of mice treated with 300 mg/kg of Ara-C or 6 
mg/kg/every other day of Doxo, exactly one week after irradiation and transplantation of 
leukemic cells. Based on the WT experiments with both Doxo and Ara-C, it was found that the 
mice were able to successfully tolerate the tested dosages. Therefore, the concentrations of both 
Doxo and Ara-C were increased for this experiment. Both groups achieved an LC(0) after 19 days 
of treatment. The 1 week leukemic Doxo mice were given a total of 6 doses, and survived for 19 
days. The 1 week leukemic Ara-C mice were given a total of 7 doses and also survived 19 days. 
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Figure 15: Kaplan Meier Curve of 1 Week Leukemic Mice Treated with 
Ara-C or Doxo.  The dose regimes for these mice were 300 mg/kg Ara-C or 6 
mg/kg Doxo, every other day, for 19 days.  
 
 Figure 16 shows three groups of leukemic mice administered treatment with PBS, Ara-C 
or Doxo as in Figure 15, except administration began exactly 4 weeks post transplantation. The 
group treated with Ara-C was given 9 doses every day, completing 1 session of treatment, and 
surviving a total of 38 days with an LC(0). The mice treated with Doxo were given 6 doses and 
survived a total of 39 days with an LC(0).  
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Figure 16: Kaplan-Meier Curve of Leukemic Mice Treated 4 Weeks 
After Transplantation with PBS, Doxo, or Ara-C.  The drug dosages 
were as described in the previous figure.  
 
 
Figure 17 shows the FACS analysis of peripheral blood and bone marrow samples 
stained for cKit which indicates the presence of leukemia, from a mouse transplanted with AML 
and treated with Doxo 4 weeks post transplantation. The pink box on the right shows the 
percentage of cells that are positive for cKit. As shown in Figure 17, less than 1% of the cells 
were positive for leukemia. Therefore, the mice did not die of leukemia. 
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Figure 17: FACS Analysis of Peripheral Blood and Bone Marrow Cells in a 4 Week 
Post-Transplantation Leukemic Mouse Treated with Doxo.  The drug regime was as 
described in the previous figure. 
 
Figure 18 shows the FACS analysis of peripheral blood samples stained for cKit from 
another mouse transplanted with AML and treated with Doxo 4 weeks post transplantation. The 
pink box on the right shows the percentage of cells that are positive for cKit, which indicates the 
presence of leukemia. 
 
Figure 18: FACS Analysis of 4 Week Leukemic Mouse Treated with Doxo. 
 
Figure 19 shows FACS analysis of peripheral blood samples stained for cKit from a 
mouse transplanted with AML and treated with PBS 4 weeks post transplantation. The pink box 
on the right shows the percentage of cells that are positive for cKit, which indicates the presence 
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of leukemia.  In the mouse treated with PBS, note the strong appearance of c-Kit+ leukemic cells 
in the peripheral blood (4.02%) compared to 0.75% for a mouse treated with Doxo. 
 
 
Figure 19: FACS Analysis of 4 Week Leukemic Mouse Treated with PBS. 
 
Blood samples were collected from mice to analyze the cell morphology to determine if 
they were dying from leukemia, or from drug toxicity (Figure 20).  White blood cells were only 
observed in the mice receiving PBS treatment (Panel A), not in mice receiving Doxo (Panel B) 
or Ara-C (Panel C).  Thus it was determined that the drug-treated mice were dying from 
cytopenia, specifically low white blood cell counts, or leukopenia.  
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Figure 20: Microscopy of Blood Smears of Leukemic Mice Treated 4 Weeks Post 
Transplantation (40x).  A. Blood smear of leukemic mouse treated with PBS 4 weeks post 
transplantation. Examples of white blood cells are in circles, and examples of red blood cells are 
in squares. There is a normal distribution of white blood cells among red blood cells. B. Blood 
smear of leukemic mouse treated with Doxo 4 weeks post transplantation. There are no white 
blood cells present on the slide, indicating an extremely low presence of WBCs in the mouse’s 
bloodstream. C. Blood smear of leukemic mouse treated with Ara-C 4 weeks post 
transplantation. There are no white blood cells present on the slide, indicating an extremely low 
presence of WBCs in the mouse’s bloodstream. 
 
 In order to compare the timing of the Doxo treatment relative to the length of 
transplantation of the leukemic cells, two groups containing four mice each were treated with the 
previously established HTD of Doxo (6 mg/kg/every other day), one group was treated 1 week 
after irradiation and transplantation with 5x105 leukemic cells, while the second group was 
treated 4 weeks after irradiation and transplantation with 5x105 leukemic cells (Figure 21). The 
first group had and LC(100) after 19 days of treatment, and the second group had an LC(100) after 
40 days of treatment. A third group of four mice was treated with PBS, and mice survived past 
day 40, with 100% survival.  Thus, treatment with Doxo at 6 mg/kg killed the mice faster if the 
mice were only 1 week post-leukemic cell transplantation. 
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Figure 21: Kaplan-Meier Curve of 1 Week vs. 4 Week Leukemic Mice 
Treated with Doxo. 
 
In order to compare the Ara-C treatment with time of leukemic cell transplantation, two 
groups with four mice each were treated with the previously established HTD of Ara-C (300 
mg/kg/every day), one group was treated exactly 1 week after irradiation and transplantation 
with 5x105 leukemic cells, while the second group was treated 4 weeks after irradiation and 
transplantation with 5x105 leukemic cells (Figure 22). The first group had an LC(100) after 19 
days of treatment, and the second group had an LC(100) after 39 days of treatment.  The third 
group of four mice treated with PBS all survived past day 40, with 100% survival. 
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Figure 22: Kaplan-Meier Curve of 1 Week Versus 4 Week 
Leukemic Mice Treated with Ara-C. 
 
 
The peripheral blood of the mice in the Ara-C experiment of Figure 22 was analyzed by 
FACS for c-Kit (Figure 23).  The pink box on the right shows the percentage of cells positive for 
cKit, which indicates the presence of leukemia. Since less than 1% of the cells contain leukemia, 
the mice died from other causes. 
 
 
Figure 23: FACS Analysis of 4 Week Leukemic Mouse 
Treated with Ara-C. 
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Because all leukemic mice in each chemo group died in the previous experiments, new 
groups of mice to be injected with lower doses of chemo drugs were established. As there was 
only time to study one drug at this point during the project, Ara-C was chosen.  The dosage 
concentration of Ara-C was lowered from 300 to 200 mg/kg, however the number and frequency 
of doses was kept the same. Also, another group was added to test the possible toxic combination 
of irradiation and treatment with Ara-C on the mice. The three groups of mice tested included a 
group of 6 mice irradiated and transplanted with 5x105 leukemic cells, and administered 200 
mg/kg of Ara-C, a second group of 5 mice that was irradiated only, not transplanted with 
leukemia, and administered the same dose of Ara-C, and a third group that was irradiated and 
transplanted with 5x105 leukemic cells and treated daily with PBS.  
Figure 24 shows the survival of these mice.  The first group, which consisted of 6 mice 
that were irradiated and transplanted with leukemia, was given 9 doses, and survived for 16 days 
with an LC(100). The second group, which consisted of 5 mice that were irradiated only, were 
given 8 doses and survived for 15 days with an LC(100).  The group of irradiated and transplanted 
mice treated with PBS survived for 16 days with an LC(0).  The irradiated non-transplanted Ara-
C mice died as quickly as the irradiated transplanted Ara-C mice, while the irradiated 
transplanted non drug treated mice survived, indicating the radiation treatment coupled with the 
toxic drug may severely weaken the mice. 
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Figure 24: Kaplan-Meier Curve of Irradiated/Transplanted Mice 
Versus Irradiated-Only Mice Treated with Ara-C. 
 
 
A final experiment was performed to determine if the mice would survive longer simply 
by administering the dose of 200 mg/kg of Ara-C every other day instead of every day.  Group-1 
contained 8 mice, irradiated and transplanted with 5x105 leukemic cells, and treated with 200 
mg/kg/every other day of Ara-C.  Group-2 contained 8 mice, irradiated and transplanted with 
5x105 leukemic cells, treated with 150 mg/kg/every other day of Ara-C. 
Group 3 contained 9 mice, irradiated only, and treated with 200 mg/kg/every other day of Ara-C.  
Group 4 contained 7 mice, irradiated and transplanted with 5x105 leukemic cells, treated with 
PBS every other day.   Figure 25 shows the survival of the four groups.  Groups 1 and 3 
survived the first session of treatment with an LC(25), which is a significant improvement from 
the LC(100) of the previous experiment.  
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Figure 25: Kaplan-Meier Curve of Leukemic Mice and Irradiated Control 
Mice Treated with 200 mg/kg of Ara-C. 
 
 
Table VI shows the organ weight in grams of mice sacrificed or found dead in this entire 
project.  Organ weight data was collected from the 1 week post transplantation group treated 
with Doxo, the 1 week post transplantation group treated with Ara-C, the 4 week post 
transplantation group treated with Doxo, the 4 week post transplantation group treated with Ara-
C, the 4 week post transplantation group treated with PBS, the first set of mice that were 
irradiated only and treated with Ara-C, the first set of mice that were irradiated, transplanted with 
AML, and treated with Ara-C, the second set of mice that were irradiated only and treated with 
Ara-C, and the second set of mice that were irradiated, transplanted with AML, and treated with 
Ara-C.  Through necropsy, the spleen, stomach, and liver were extracted and weighed, to 
identify the cause of death of the mouse. An enlarged spleen signifies death by leukemia, 
whereas an enlarged stomach or liver signifies death by drug toxicity.  The necropsy of the mice 
treated 4 weeks post transplantation indicated the majority of mice treated with Doxo or Ara-C 
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had a spleen weight of approximately 0.1 gm, while mice treated with PBS had a spleen weight 
of approximately 0.5 gm. The average spleen weight of a wild type mouse is 0.07-0.1g (Yan et 
al, 2002).  Since an enlarged spleen often characterizes the presence of leukemia, this suggests 
that mice treated with the chemo drugs did not die from AML. 
 
Table VI: Necropsy Data-Organ Weights. 
Type of Mouse
Spleen Liver Stomach
1 week Doxo - - 1.43
1 week Ara-C - - 3.11
1 week Ara-C - - 2.62
4 week Ara-C 0.105 - -
4 week Doxo 0.118 - -
4 week Doxo 0.158 - -
4 week Ara-C 0.813 1.57 -
4 week Ara-C 0.23 1.08 -
4 week Doxo 0.063 - -
4 week PBS 0.48 - -
1. Irr only+Ara-C 0.006 1.07 3.55
1. Irr only+Ara-C 0.019 0.82 2.9
1. Irr only+Ara-C 0.06 0.67 2.71
1. Irr only+Ara-C 0.08 0.86 2.11
1. Irr only+Ara-C 0.05 1.09 2.83
1. Irr+AML+Ara-C 0.01 0.712 2.76
1. Irr+AML+Ara-C 0.028 0.83 1.85
1. Irr+AML+Ara-C 0.019 0.58 0.82
1. Irr+AML+Ara-C 0.01 1 1.68
1. Irr+AML+Ara-C 0.38 0.81 1.88
1. Irr+AML+Ara-C 0.1 0.98 0.6
2. Irr+AML+Ara-C 0.045 0.687 0.431
2. Irr+AML+Ara-C 0.063 0.429 0.532
2. Irr only+Ara-C 0.05 0.71 0.61
2. Irr only+Ara-C 0.008 0.78 0.55
Weight (grams)
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5.0   DISCUSSION 
 
 The primary goal of this project was to design a Doxo or Ara-C treatment regime to 
decrease the toxic effect of these key chemotherapy drugs in the leukemia transplantation mouse 
model while increasing drug efficacy. This goal was accomplished by establishing an appropriate 
drug concentration, dose and schedule. In order to accomplish the primary goal of the project, 
experiments were conducted in three stages. The first stage involved in vitro drug testing using 
3T3, ME-1, and mouse leukemic cells. The second stage included in vivo drug testing with WT 
mice.  The third stage of the project included in vivo drug testing in the leukemia transplantation 
model.  
 
5.1  In Vitro Drug Testing 
 During the in vitro experiments, 3T3 cells were used as a marker for comparison with 
ME-1 cells. It was expected that the 3T3 cells would be affected by the chemotherapy drugs, as 
3T3 cells have a rapidly proliferating cell cycle that can double in 24 hours. Doxo had a 
cytotoxic effect on the 3T3 cell line, as the majority of these cells were in the apoptotic state of 
the cell cycle. Ara-C had a cytostatic effect on this cell line, as the majority of these cells were in 
the G1 phase of the cell cycle. There was little difference between the cells treated with a volume 
of 10 µL of Ara-C in G1 phase and control cells in G1 phase. Therefore in future experiments, 
lesser volumes of Ara-C can be used to achieve the same result.  
 It was originally expected that the ME-1 cells, which carry the inv(16)mutation that 
produces AML, would be affected by the various concentrations of Doxo and Ara-C after the 24 
hour incubation period. However, the ME-1 cells were unaffected by 24 hour incubation with the 
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chemotherapy drugs because the cell cycle is longer than 24 hours. While chemotherapy drugs 
are cytotoxic and, since ME-1 and some other AML cells have “frequently low DNA synthesis 
rates”, it would take an extended period of time for the chemotherapy drugs to have an effect on 
their cell cycles (Butturini, 1990). This experiment was repeated to determine how these drugs 
affect the cell cycle at various incubation time points. PI analysis was performed at 24 hours, 48 
hours, 72 hours, and 120 hours after initial incubation with Doxo and Ara-C. However, we were 
unable to obtain results from these experiments with extended time points because there were not 
enough cells to be analyzed through FACS analysis due to difficulty culturing ME-1 cells. In the 
future, it may be beneficial to repeat these experiments with a stock of ME-1 cells that will 
survive throughout the various incubation time points.  
 The same experiment was repeated with leukemic cells harvested from a mouse with 
AML and we were not able to obtain results due to cell death in culture. This may have been 
caused by the decrease in viability over time of the cryopreserved cells. The procedures for 
cryopreserving and culturing these leukemic cells need to be fine-tuned in order to ensure cell 
growth and survival throughout the duration of the experiment.   
 
5.2 In Vivo Drug Testing in WT Mice 
 In order to gain a better understanding of the toxicity and efficacy of Doxo and Ara-C as 
treatment options for AML, toxicity experiments were first conducted on WT mice. The dosage 
concentrations and schedule found to work most efficiently with little toxic effect on the mice 
differed from previously published data. It was previously determined by Lee et. al that mice are 
able to tolerate 3 mg/kg every three days for three dosages of Doxo. However, we found that WT 
mice can tolerate up to 6 mg/kg every other day for ten dosages of Doxo. The strain of mice used 
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in the two experiments varied, which led us to conclude that the WT 129 SvEv mouse strain used 
in this project is less sensitive to the toxicity of these drugs and can tolerate a much higher 
dosage of Doxo for an extended period of time than the FVB/N mice used in the Lee et. al study.  
 Similarly, during the Ara-C toxicity experiments in WT mice, we found that the 129 
SvEv mice could tolerate higher concentrations over a longer period of time than the strains of 
mice used in previously published studies.  In a study by Largaespada, mice were able to tolerate 
two sessions of 9 injections with 100 mg/kg of Ara-C, with a one week rest period between the 
two sessions. The mice from the published data had an LC(25), and while the 129 SvEv mice we 
analyzed also had an LC(25), the dosage concentration and schedule exceeded the study from the 
published data. The 129 SvEv mice used in our experiments were given three sessions of 9 
injections with 200 mg/kg of Ara-C, with a one week rest period between the first and second 
sessions, and a fourteen day rest between the second and third sessions. Again, this proved that 
the WT 129 SvEv strain of mice have a higher tolerance for Doxo and Ara-C treatments. It 
appears that we cannot transfer data about drug tolerance from one strain to another. In addition, 
the dosages and concentrations of treatment from previously published studies were performed 
on mice that were irradiated and transplanted with leukemic cells. In our toxicity experiments, 
the effect of irradiation on the mice was not taken into account, which may be an explanation as 
to why the WT 129 SvEv mice were able to tolerate such high doses of the chemotherapy drugs 
for an extended length of time.  
 
5.3  In Vivo Drug Testing in the Leukemia Transplantation Model 
 The concentrations and dosage schedules determined in wild type mice were used as a 
starting point to establish treatment with chemotherapy drugs in the mice transplanted with 
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AML. We wanted to observe the efficacy of each drug at preventing the progression of leukemia, 
and in the treatment of leukemia after it had developed to a more advanced stage. Therefore, we 
began injections at two different time points, 1 week post transplantation and 4 weeks post 
transplantation. The mice that were treated 1 week post transplantation died only 19 days after 
the initial transplantation, while the mice treated after 4 weeks post transplantation died after 39 
days. A possible reason why the 1 week post transplantation mice died so quickly may be a result 
of the irradiation causing the immune systems of the mice to become weakened and fragile. The 
4 week post transplantation mice had an additional three weeks to recover from irradiation and 
strengthen their immune systems to be able to better tolerate the toxicity of the chemo drugs. It 
was determined that from a survival perspective, it would be more efficient to administer 
chemotherapy treatment four weeks after irradiation.  
 The necropsy of the mice treated 4 weeks post transplantation indicated the majority of 
mice treated with Doxo and Ara-C had a spleen weight of approximately 0.1g, while mice 
treated with PBS had a spleen weight of approximately 0.5g. The average spleen weight of a WT 
mouse is 0.07-0.1g (Yan et al, 2002). Since an enlarged spleen often characterizes the presence 
of leukemia, this suggests that mice treated with the chemo drugs did not die from AML.  It is 
apparent from the enlarged spleen weight, as well as the presence of cells positive for cKit, the 
marker for leukemic cells, that the mice treated with PBS died of leukemia.  
From analysis of cell morphology, it was determined that mice treated with Doxo and 
Ara-C 4 weeks post transplantation had extremely low white blood cell counts. Since leukemia 
did not appear to be the cause of death for these mice, this led to the conclusion that the mice 
died of cytopenia, most likely caused by the toxicity from the treatments with Doxo and Ara-C.  
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 In order to gain better insight into the cause of death of the mice, a second set of 
experiments was performed, however, only Ara-C was used as a treatment due to the time 
restraints of the project. During these experiments, three groups of mice were treated. These 
groups included the first group of mice that was irradiated, transplanted with AML and treated 
with 200 mg/kg of Ara-C, a second group that was irradiated-only and treated with 200 mg/kg of 
Ara-C, and a third group that was irradiated, transplanted with AML and treated with PBS. The 
first two groups began dying after the 6th injection, and all mice in this group were dead by the 
9th injection. The second group, that was irradiated but was not injected with AML cells, served 
as a control to determine if the combination of irradiation and drug toxicity was leading to the 
premature death of the mice. Since this second group died at the same time and rate as the first 
group, this proved that it was the combination of the toxicity of the drug and irradiation which 
killed them as opposed to the combination of the toxicity of the drug and the leukemia that was 
originally thought to be killing the mice.  
 As a result of the mice dying after the 9th injection, similar experiments were performed 
treating the mice every other day with 200 mg/kg instead of treating the mice daily with Ara-C. 
We also added a second group of mice treated with only 150 mg/kg every other day. This helped 
to determine if the daily dosages of 200 mg/kg were too toxic on the internal systems of the 
mouse’s body. We determined that the mice treated with 200 mg/kg every other day survived 
with a LC(25) up to the 9th injection at day 24, compared to the LC(100) at the 9th injection at day 
16 for the mice treated every day. The 150 mg/kg had an LC(0) up to the 9th injection by day 24. 
Therefore, the treatment of 200 mg/kg of Ara-C every other day was less toxic to the mice, and 
this combination of irradiation and treatment increased mouse survival by 75% after 5 injections.  
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 The results obtained in these experiments support the conclusion that a balance between 
drug toxicity and AML prevention must be found. Although these drugs killed the leukemic 
cells, they also killed normal, proliferating cells resulting in mouse death. While the wild type 
mice were able to tolerate high dosages of Doxo and Ara-C, the irradiation enhanced the toxic 
effects of each drug in the leukemic model. However, when the dosages of each drug were 
lowered and the mice were given time to recover from the irradiation, the mice survived longer 
without showing signs of leukemia. Our research shows that two important factors in decreasing 
the toxicity and increasing the efficacy of AML treatment are the amount of recovery time post 
irradiation and the concentration of drug dose. 
 In order to improve treatment for patients with AML, a balance between drug toxicity 
and efficacy must be determined.  This established treatment can be combined with other 
compounds, which could potentially inhibit activity of the oncoprotein CBFβ-SMMHC.  The 
Doxo and Ara-C compounds tested here were previously found by a high through put screen and 
have the potential to specifically target AML cells. With a combined treatment the chemo drugs 
might eliminate the existing leukemic cells and prevent the formation of new leukemic cells 
expressing the oncoprotein CBFβ-SMMHC. We hope that these findings contribute to potential 
new therapies that will improve the long term remission rates of patients suffering from AML.  
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